Literature DB >> 11791619

Cardiac amyloidosis associated with the transthyretin Ile122 mutation in a Caucasian family.

K Hamidi Asl1, M Nakamura, T Yamashita, M D Benson.   

Abstract

The Ile122 transthyretin variant associated with restrictive cardiomyopathy has been described in African-Americans and estimated to be present in approximately 4% of the Black population. We report the first American-Caucasian family with cardiomyopathy due to the TTR Ile122 mutation. The high prevalence of this mutation in the Black population and the discovery that it may cause disease in other ethnic populations highlights the importance of considering this autosomal dominant systemic amyloidosis in all individuals with restrictive cardiomyopathy. Inadequate diagnosis combined with inappropriate treatment may have a significant impact on morbidity and mortality.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11791619     DOI: 10.3109/13506120108993823

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  3 in total

1.  Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies.

Authors:  Joel Buxbaum; Alice Alexander; James Koziol; Clement Tagoe; Ervin Fox; Dalane Kitzman
Journal:  Am Heart J       Date:  2010-05       Impact factor: 4.749

2.  The Val142Ile transthyretin cardiac amyloidosis: more than an Afro-American pathogenic variant.

Authors:  Federico Perfetto; Sabrina Frusconi; Franco Bergesio; Elisa Grifoni; Alessia Fabbri; Costanza Giuliani; Serena Falconi; Stefania Bonifacio; Francesco Cappelli
Journal:  J Community Hosp Intern Med Perspect       Date:  2015-04-01

3.  The prevalence and distribution of the amyloidogenic transthyretin (TTR) V122I allele in Africa.

Authors:  Daniel R Jacobson; Alice A Alexander; Clement Tagoe; W T Garvey; Scott M Williams; Sara Tishkoff; David Modiano; Sodiomon B Sirima; Issa Kalidi; Amadou Toure; Joel N Buxbaum
Journal:  Mol Genet Genomic Med       Date:  2016-07-14       Impact factor: 2.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.